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Results: Five hundred and seventy-five patients were included, 
254 treated with RP and 321 with PB. At RP, 24% had pT3 disease. 
The positive surgical margin rate was 50% and 21% for patients 
with pT3 and pT2 respectively. The median D90 (dose [Gy] that 
covers 90% of the prostate volume) in this study was 159.1 Gy 
(IQR 140.9-176.7 Gy). The D90 was < 130 Gy in 14% of implants. 
Patients who had RP were compared to patients treated with PB: 
RP patients were significantly younger, had less positive pre-
treatment biopsies but a lower rate of Gleason 7 disease. The 
mean PSA was not different. The rate of patients with BCR was 
not different between both groups (p = 0.24) and occurred in 
21.2% after RP and in 20.6% after PB. On univariate and 
multivariate logistic regression analysis, younger age, higher 
percentage of positive biopsies and initial PSA were predictive of 
BCR. Treatment modality was not predictive in either univariate 
(OR 0.96, 95%CI 0.64-1.44 p = 0.58) or multivariate (OR 1.42, 
95%CI 0.88-2.28, p = 0.42) analyses. 
Conclusions: Both RP and PB result in similarly good results at 
four years post treatment with about 20% experiencing BCR, as 
measured with similar PSA-thresholds. Clinical T-Stage, age, 
percentage of positive biopsies and Gleason score are predictive 
of outcome. However, it is possible that study power is 
inadequate and/or follow up is too short to detect a difference 
between both treatments. 
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Purpose: To investigate the effect of D90 on biochemical failure 
in a large consecutive cohort of I125 monotherapy patients. 
Methods and Materials: Between July 1998 and September 2011, 
3436 men with NCCN low- and intermediate-risk prostate cancer 
underwent I125 brachytherapy monotherapy, 3392 (98.6%) of 
whom had post-implant, CT-based dose metrics recorded. Sixty 
percent had intermediate-risk disease and 46% had six months of 
neoadjuvant/concomitant androgen deprivation therapy (ADT). 
The median D90 was 153 Gy (mean 154 Gy, SD 15.9, range 86.5-
223 Gy).The median follow up was 5.48 years (mean 6.12, SD 
3.95, range 0-16.9); 648 men have been followed for at least 10 
years. 
Results: As of September 2015, there have been 222 biochemical 
relapse events (nadir+2 ng/mL threshold) yielding five- and 10-
year K-M biochemical progression free survival (b-PFS) estimates 
of 94.9% (± 1.0%) and 89.9% (± 1.6%) respectively. Intermediate-
risk patients were more than twice as likely to experience 
biochemical failure compared to low-risk (HR 2.13, p < 0.001). In 
a multivariate Cox model, Gleason sum 7 versus ≤6 (HR 2.2, p < 
0.001), pre-treatment PSA (HR 1.14 per unit increase, p < 0.001) 
and clinical T2b-c versus T1c-T2a (HR 1.8, p < 0.001) were each 
strongly associated with increased risk of biochemical failure. 
The use of ADT reduced the risk of biochemical failure (HR 0.51, 
p < 0.001). Post-implant D90 values, age and percent positive 
cores were not statistically associated with biochemical relapse 
in MVA. Although not reaching statistical significance, a small 
dose effect was identified when comparing the annualized risk 
of relapse for years 4-9 post-implant permitting a quantitative 
estimate of the impact of D90 on b-PFS. For intermediate-risk 
patients who did not receive ADT (n = 1019), D90 had no 
measurable impact on the risk of biochemical failure. However, 
for the intermediate-risk patients who did receive ADT (n = 
1085), there was a 1.8% improvement in the ten-year b-PFS for 
each 10 Gy increase in D90. For the low-risk patients, there was 
a 1.4% improvement in the ten-year b-PFS for each 10 Gy 
increase in D90. 
Conclusions: The three conventional prognostic factors (Gleason 
sum, pre-treatment PSA and clinical T-Stage) as well as the use 
of ADT were all strongly associated with biochemical failure in 
MVA. D90 did not reach statistical significance in MVA, but a 
small beneficial effect of increased D90 values was identified. 
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Purpose: To report preliminary outcomes of focal salvage HDR 
brachytherapy for locally recurrent prostate cancer after 
external beam radiotherapy (RT). 
Methods and Materials: All 15 patients entered on a prospective 
study had biopsy proven locally recurrent prostate carcinoma 
visible on MRI, at least 18 months after definitive RT, with > 6 
months PSA doubling time. The GTV was defined using 
multiparametric MRI (T2-weighted, diffusion-weighted, dynamic 
contrast-enhanced). The prostate gland and GTV contours were 
deformably co-registered to T2w images at time of 
brachytherapy after catheter placement using deformable image 
registration. CTV margin expansion (5 mm in all directions) was 
restricted to adjacent OARs and 2 mm beyond the prostate 
boundary where applicable. PTV margins of 2 mm cranio-caudally 
and 1mm elsewhere were then applied. A total dose of 26 Gy in 
two separate implants 7-14 days apart was delivered. No patient 
received androgen deprivation therapy. 
Results: Median follow up was 12 months (range, 3-24). The 
median age at time of enrollment was 72 years (range, 62-77). 
The median pre-brachytherapy PSA was 3.96 ng/ml (range, 1.68 
– 8.39). All patients had a single GTV. Median GTV and PTV 
volumes were 1.45 cc (range, 0.66-6.76) and 6.45 cc (range 3.5-
17.39), respectively. A median of eight catheters (range, 4-12) 
were used. Initial biochemical response after salvage 
brachytherapy was seen in all patients with 14 having > 50% 
reduction from baseline. To date 10 have achieved PSA < 1 
ng/ml, while 10 of 12 patients with > 12 months follow up have 
PSA level < 1 ng/ml. Of two patients who have experienced 
biochemical failure, one had imaging and biopsy evidence of a 
marginal recurrence. Acute toxicity (CTCAE v4.0) was mild. Only 
one patient had Grade 2 toxicity (temporary urinary 
catheterization after his second implant). All acute toxicity has 
resolved in patients who have greater than three months of 
follow up. 
Conclusions: MR-guided focal salvage HDR brachytherapy in 
patients treated with previous RT is associated with minimal 
acute toxicity and initial biochemical response appears 
promising. Further follow up will determine if this approach 
results in acceptable local/biochemical control and late toxicity. 
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Purpose: Exposure of the heart to radiation during radiotherapy 
for breast cancer has been shown to increase the rate of ischemic 
heart disease, with the increase being proportional to the mean 
dose to the heart. Although a significant reduction of heart dose 
has been shown with respiratory-gated irradiation of the left 
breast, there is currently no data on heart dose variation through 
the cardiac cycle. The purpose of this study was to assess dose 
variation to left coronary artery, left ventricle and heart during 
the cardiac cycle using dual source computed tomography 
(DSCT). 4D cardiac motion was used to investigate the potential 
dosimetric advantage of cardiac-gated radiotherapy.  
Methods and Materials: This is a prospective pilot study of 
patients with left-sided breast cancer treated with tangential 
breast irradiation. A planning scan and a contrast-injected 
